Key Drivers
- Cash flow strength
- Margin compression
- Debt coverage risk
AIAI Summary
Takeda now looks less like a stable legacy cash cow and more like a pipeline-dependent turnaround: if late-stage assets like zasocitinib and Entyvio expansion convert while cash flow stays strong, the stock can re-rate, but continued revenue erosion, legal drag, and weak interest coverage make the current valuation too early to trust without execution follow-through.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash flow strength
- •Margin compression
- •Debt coverage risk
Tak has a strong asset base and cash flow, but thin margins, persistent losses, weak interest coverage, and tight liquidity make the investment case risky.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Breakout hold
- •Stretch risk
Over the last month, TAK rallied from near $15.03 to $16.77 and broke above $16.00 on 2026-07-02, making the short-term trend modestly bullish but still dependent on follow-through above resistance.
Abrupt jump above the prior range may be short-term extended
Sentiment & News
Key News Insights:
- •Psoriasis upside
- •FDA milestone
- •AI expansion
Takeda is seeing strong June–July 2026 momentum, with late-stage wins in psoriasis and narcolepsy, FDA progress for ENTYVIO, a major CEO transition, and a new AI discovery partnership that reinforces growth and innovation.
The news is broadly positive for Takeda, reinforcing confidence in its pipeline execution, regulatory progress, and strategic innovation efforts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings